South Korea
South Korea

Time filter

Source Type

News Article | May 15, 2017
Site: www.prweb.com

California Casualty will be giving one lucky first responder the chance to “choose their tools” in the latest Work Hard/Play Hard Sweepstakes. The grand prize is an ultimate package of up to $5,000 worth of DeWALT®* guaranteed tough tools. The winner will choose from an impressive catalogue that includes: generators, compressors, tool storage units, and all the power saws, wrenches, drills, and accessories anyone could ever need or use. The $5,000 Work Hard/Play Hard drawing is open to peace officers, EMTs and firefighters; American heroes who work hard and risk their lives daily. Entries are being taken now through November 13, 2017 at http://www.policefiregiveaway.com. “We know the pressure and stress first responders face every day,” said California Casualty Sr. Vice President Mike McCormick. “This is our chance to show our appreciation and provide a useful and fun way to say thanks.” The most recent Work Hard/Play Hard contest recipient was California firefighter Ken H., who opted for the cash instead of his choice of DeWALT® tools in November 2016. The prize made a big difference for Ken, who applied the money towards college tuition for his two sons. “I go to work each day knowing that I can make a difference in someone’s life, even in some of their worst moments,” Ken said at the time. Forget having to borrow tools again, enter the California Casualty “Choose Your Tools” Sweepstakes. The entry form and rules can be found at http://www.policefiregiveaway.com. The deadline to enter is November 13, 2017, with a winner announced in December. First responders can learn more about California Casualty and how it appreciates all they do at https://mycalcas.com. Entrants must be a currently employed/volunteer or retired Peace Officer, Firefighter, or be an Emergency Medical Technician (EMT). Entrants must be 18 as of May 15, 2017 and a resident of the fifty (50) United States and the District of Columbia. Residents of AK, HI, MA, MI, NC, NY, RI and WI are NOT eligible. In the following states, a resident must be a member of the associated group to be eligible: AZ, CA, CO, KS, KY, IN, IL, IA, LA, MA, MD, MO, NE, OH, OR, TX, WA and UT. Headquartered in San Mateo, California with Service Centers in Arizona, Colorado and Kansas, California Casualty provides auto and home insurance to educators, firefighters, law enforcement and nurses across the country. Founded in 1914, California Casualty has been led by four generations of the Brown family. To learn more about California Casualty, or to request an auto insurance quote, please visit http://www.calcas.com or call 1.800.800.9410. *DeWALT® is a registered trademark of Stanley Black & Decker. All rights reserved. DeWALT® and its parent companies are not participating partners in or sponsors of this contest.


News Article | May 14, 2017
Site: www.prweb.com

On December 8, 2015, Engine Company 28 (West Lanham Hills) responded to a working house fire in Hyattsville, Maryland and the all-volunteer crew of five personnel proceeded to extinguish the fire within a few short minutes of arrival. Also on the scene of the incident was a three-person crew of paid firefighters (Prince George’s County employees) from a nearby station. The two female members from that engine company alleged that they were prevented from entering the house and further claimed that the two male volunteers from Engine Company 28 pushed and fought with them while the other volunteers were finishing the extinguishment of the fire. However, these allegations proved to be untrue, said Scott Vazquez, President of the West Lanham Hills Volunteer Fire Department. The State’s Attorney for Prince George’s County issued a statement in December of 2016, announcing the charges against the two volunteers: then-Assistant Fire Chief Jeffrey Miller and Firefighter/EMT Christopher Kelly. That statement and other media reports attempted to highlight the fact that the allegations were not only by career (paid) firefighters against volunteer (unpaid) firefighters, but also the male / female aspect of the accusations. Brian R. Bregman, the attorney for the West Lanham Hills Volunteer Fire Department, which is one of only a small few 100% all-volunteer fire stations in Prince George’s County, commented “We feel that the public statements, made by Prince George’s State’s Attorney Angela Alsobrooks immediately after her office filed the charges in this case, were unfair, premature, and designed for maximum political impact. I will not repeat them because they should not have been made in the first place or before our system of justice was finished.” President Vazquez also noted that, “Then-County Fire Chief Marc S. Bashoor made public comments after this incident first occurred, insinuating that Company 28 and its volunteers were somehow responsible, which again proved to be wrong after a jury of twelve citizens of this County were finally able to hear all of the evidence.” Mr. Bregman, who represented Kelly at the 5-day trial in Upper Marlboro, said, “The exoneration of these fine volunteer members is a reminder that accusations should never be reported as fact or certainty. These men never committed any crimes whatsoever. They merely did their jobs and did them well, putting the fire out and protecting lives and property. The complainants eagerly leapt at the chance to ‘cry wolf’ for political, financial, and other ulterior motives. It was further aggravated when the government chose to side with the career personnel in this situation, perhaps because of the male-female undertones that they saw an opportunity to create, and despite an unbelievable amount of evidence showing that these members were innocent—evidence that even included videos and photographs.” There were other egregious violations of the members’ rights, Mr. Bregman said, including their right to a speedy trial because the State’s Attorney’s Office took nearly a year just to present the charges even when they failed to conduct an investigation. He also reported that the claims and allegations were all but completely discredited and exposed during the trial. Prince George’s County, Maryland has the largest combination volunteer and career fire department in the United States of America. “It also has the strongest, most experienced, and most dedicated volunteer professionals of any combination department, anywhere,” President Vazquez stated. Mr. Bregman, on behalf of the volunteer station, made the following remarks: “Volunteer public safety workers such as firefighters, EMTs, and paramedics generally expect certain hazards when they serve and protect the public. These men and women are exposed to harsh and dangerous conditions. They have a surprisingly high rate of heart attacks, high blood pressure, and even cancer as compared with other occupations. However, never do they imagine that politics and personal agendas would be allowed to put their freedoms and families at risk. These two gentlemen can now return to their personal lives and full-time careers with some semblance of normalcy. I just hope that, after this ordeal, we have not lost them as ‘volunteer professionals’ in our community.” At trial, Volunteer Firefighter/EMT Christopher Kelly was represented by Attorney Brian R. Bregman of Laurel, Maryland, and Volunteer Assistant Fire Chief Jeffrey Miller was represented by Ann E. Koshy and Patrick J. McAndrew of Greenbelt, Maryland. The case was heard in the Circuit Court for Prince George's County, Maryland, Case Nos. CT161455A (Miller) and CT161455B (Kelly).


News Article | May 11, 2017
Site: www.eurekalert.org

The low oxygen concentrations that prevail in many tumors enhance their propensity to metastasize to other tissues. Researchers at Ludwig-Maximilians-Universitaet (LMU) in Munich led by Professor Heiko Hermeking have now uncovered the molecular mechanism that links the two phenomena. Many actively growing tumors are poorly supplied with blood, which limits the concentration of oxygen available within the tumor, a condition known as hypoxia. Tumor hypoxia has several significant consequences: The relative lack of oxygen partly accounts for the fact that such solid tumors are comparatively resistant to radiation and chemotherapy, and it also promotes the formation of satellite tumors in other tissues. Now researchers led by LMU professor Heiko Hermeking have dissected the mechanisms responsible for the association between tumor hypoxia and metastasis. Their results reveal how hypoxia leads to inhibition of the synthesis of a short RNA molecule that normally suppresses tumorigenesis. The new findings appear in the journal Gastroenterology. Cancers can only develop if the biochemical circuits that control cell proliferation and behavior are inactivated. These safe-guarding mechanisms are mediated by so-called tumor-suppressor proteins, one of which is known as p53. The gene encoding p53 is inactivated in more than half of all tumors. In previous studies Hermeking had shown that p53 induces the transcription of a short RNA - referred to as microRNA-34a (miR-34a) - which plays a central role in tumor suppression. "We observed that, in patients with colon carcinomas, the gene for miR-34a is very frequently inactivated in metastasizing tumors, which are often characterized by relative oxygen deficiency," Hermeking says. He and his colleagues have now shown that, in tumor cells in which the p53 function is compromised, complete loss of miR-34a expression is a direct consequence of hypoxia. In response to low oxygen levels, the tumor cells trigger the synthesis of hypoxia-inducible factor 1a (HIF1a), a protein that directly represses the transcription of miR-34a. Furthermore, this down-regulation of the microRNA is a prerequisite for hypoxia-induced epithelial-to-mesenchymal transition (EMT). In this process, HIF1a activates a genetic program that results in the transformation of non-invasive cells (which grow in a regulated fashion in epithelial sheets) into invasive, migratory cells that can seed new tumors elsewhere. EMTs play important roles in embryonic development and organogenesis, as well as in wound healing, but must be tightly regulated. Among the proteins involved in orchestrating the EMT is PPP1R11. Hermeking's team found that especially high levels of this protein are synthesized in the cells that form the leading edge of an invasive tumor - where the oxygen concentration is expected to be particularly low. In normal cells, on the other hand, the production of PPP1R11 is repressed directly by miR-34a and thus indirectly by the tumor suppressor p53. This ensures that cells divide in a coordinated manner and prevents formation of metastases. "The regulatory antagonism is presumably the reason why metastasizing tumor cells are selected for loss of the p53 gene, which is required for the expression of miR-34a," Hermeking explains. The new findings also have therapeutic implications, for they suggest that metastasizing colon tumors could perhaps be treated with drugs that inhibit the functions of proteins that promote the EMT. Such inhibitors would also be expected to permit reactivation of the expression of miR-34a. "In fact, molecules that act as functional substitutes for miR-34a are now being tested in clinical trials," says Hermeking. This miRNA is of particular interest as a drug target, because it is involved in the control of many regulatory processes. For instance, reintroduction of miR-34a into tumor cells also activates the patient's immune system to attack the tumor. Hermeking's results suggest that hypoxic tumors might be especially susceptible to this approach.


News Article | May 13, 2017
Site: www.prlog.org

-- FireandAxes.com, the leader in American Firefighter collectables, firefighter coins and firefighter shirts is pleased to announce their newest Made in American design, the Distressed EMS EMT Star of Life shirt.The Distressed EMS EMT Star of Life Shirt is made to be worn with Pride! The Distressed EMS EMT Star of Life Shirt is made for those working as EMT's and in EMS, a sometimes thankless job but one that is as important as they come.This design is printed on a 100% Made in America shirt at our facility in Florida. The design shows the letters EMS or EMT in distressed grey lettering with the Star of Life inside of the words in blue and white. A simple design, with a classic look. An impressive design you'd expect from us here at Fire and Axes. The Distressed EMS EMT Star of Life shirt.All products at FireandAxes.com must pass rigorous inspections before leaving our facility. Ensuring the best possible product for our customers. We welcome you to FireandAxes.com, browse our site. Contact us at hq@fireandaxes.com with any questions you may have.FireandAxes.com offers everything from firefighter shirts, firefighter coins and apparel to firefighter signs and firefighter collectables. All designed with the hard working American Firefighter and EMS workers in mind. We also offer loads of items that are customizable, 1 to 100 we have you covered. Already have your own design, we can print that or help you design a new one.You can check out this new design here:


News Article | May 12, 2017
Site: www.24-7pressrelease.com

MORRISTOWN, NJ, May 12, 2017-- Attorney Scott G. Leonard of Leonard Legal Group has once again been named a New Jersey Super Lawyer. This is Leonard's tenth consecutive year on the list.Leonard began practicing law in 1996. He received his undergraduate degree from the University of South Florida and then made his way up north to attend law school at Widener University School of Law in Delaware. Since then, he has served personal injury victims throughout New Jersey, taking a personal interest in providing the best possible outcome for each injured victim and their family.Attorney Leonard is Board Certified by the New Jersey Supreme Court as a civil trial attorney, a designation achieved by less than two percent of all New Jersey attorneys. In addition to consistently appearing on the New Jersey Super Lawyers list, he was also named in The National Trial Lawyers' Top 100 Trial Lawyers from 2013-2017. Leonard previously served as President of the New Jersey Association for Justice, the foremost trial lawyer organization dedicated to protecting the rights of accident victims and preserving the concept of justice for all. In his spare time he serves as a volunteer EMT. Leonard is also a frequent lecturer and moderator on various legal topics and issues and recently co-chaired the Ethics program at the New Jersey Association for Justice Boardwalk Seminar.Super Lawyers is a rating service created to establish a prestigious network of outstanding lawyers in more than 70 practice areas. Selected attorneys have attained a high degree of peer recognition and professional achievement, and are selected based on independent research by the board, and peer nominations and evaluations. For more information about Super Lawyers, visit SuperLawyers.com About Leonard Legal Group: Prominent New Jersey personal injury attorneys Scott G. Leonard and Sean Connelly handle all types of personal injury matters, including accidents, wrongful death, nursing home negligence, birth injuries and workplace accidents. They are dedicated to recovering the justice and compensation victims deserve. Their reputation for staunch advocacy and compassionate guidance was built over more than two decades. Learn more by calling 973-984-1414 or at LeonardLawyers.com


News Article | May 19, 2017
Site: www.marketwired.com

MELBOURNE, AUSTRALIA--(Marketwired - May 19, 2017) - Propanc Biopharma Inc. ( : PPCH) ("Propanc Biopharma" or "the Company"), a clinical stage biopharmaceutical company focusing on development of new and proprietary treatments for cancer patients suffering from solid tumors such as pancreatic, ovarian and colorectal cancers, today announced that fresh new insights have emerged into how cancer stem cells (CSCs) are able to resist standard treatments, become more aggressive and spread rapidly. Published in Oncogene, by researchers from the Bellvitge Biomedical Research Institute south of Barcelona, Spain, the findings have significant implications for Propanc Biopharma's lead product PRP, which reprograms CSCs so that they are no longer malignant and a threat to the patient. PRP is a solution for once daily intravenous administration of a combination of two pancreatic proenzymes trypsinogen and chymotrypsinogen. One of the authors from the study, Dr Miguel Ăngel Pujana, describes why tumors adapt to and resist certain therapies, like mTOR inhibitors, a treatment used in advanced stages of breast cancer. He links mTOR inhibition with increased expression of certain genes, like EVI1, which contributes to epithelial to mesenchymal transition (EMT), a key process by which cancer cells become stem cell-like, motile and invasive, seeding new tumors. Dr Miguel concludes, "Tumor cells are able to adapt to treatment through a phenotype (character) shift that makes them more aggressive and sustains their metastatic potential." Data from hundreds of cell lines expand on the concept that CSCs are frequently the source of therapy resistance and metastasis, the main cause of patient death from cancer. "When administering PRP to a patient, we are essentially reprogramming CSC gene expression, pushing these cells back to a normal, less malignant state, so they die naturally," said Dr Kenyon, Propanc's Chief Scientific Officer. "Reversing the EMT process is a key feature of PRP and is fast becoming a credible solution to controlling CSCs, which are responsible for cancer spreading, or metastasis, the main cause of patient death from cancer." "The latest scientific discoveries regarding CSC reprograming shows we are on the right track, which we believe is not reflected in our current market capitalization," said James Nathanielsz Propanc's Chief Executive Officer. "Nevertheless, we are advancing towards First-In-Human studies and remain excited about developing PRP as a new therapeutic approach for cancer sufferers. We remain focused on delivering long term value to our loyal shareholders." The rationale for developing PRP is based on a set of in-vitro studies on CSCs, as well as xenograft and syngeneic mouse models of ovarian and pancreatic cancers, respectively. In summary, these data indicate that the dramatic reduction of cellular markers associated with the process of EMT as a consequence of PRP treatment, could not only reverse the EMT process with the implication to stop tumor progression and metastasis, but also seem to suppress the development of CSCs. Consequently, these results are strong indicators of the therapeutic potential of PRP that could be categorized as an anti-CSC therapeutic drug. Currently progressing towards First-In-Human studies, PRP aims to prevent tumor recurrence and metastasis from solid tumors. Eighty percent of all cancers are solid tumors and metastasis is the main cause of patient death from cancer. According to the World Health Organization, 8.2 million people died from cancer in 2012. Consequently, a report by IMS Health states innovative therapies are driving the global oncology market to meet demand, which is expected to reach $150 Billion by 2020. The Company's initial target patient populations are pancreatic, ovarian and colorectal cancers, representing a combined market segment of $14 Billion predicted in 2020, by GBI Research. To view Propanc Biopharma's "Mechanism of Action" video on anti-cancer product candidate, PRP, please click on the following link: http://www.propanc.com/news-media/video To be added to Propanc Biopharma's email distribution list, please click on the following link: http://ir.propanc.com/email-alerts and submit the online request form. About Propanc Biopharma: Propanc Biopharma is a clinical stage biopharmaceutical company developing new cancer treatments initially for patients suffering from pancreatic, ovarian and colorectal cancers. We have developed a formulation of anti-cancer compounds, which exert a number of effects designed to control or prevent tumors from recurring and spreading throughout the body. Our products involve or employ pancreatic proenzymes, which are inactive precursors of enzymes. In the near term, we intend to target patients with limited remaining therapeutic options for the treatment of solid tumors. In future, we intend to develop our lead product to treat (i) early stage cancer and (ii) pre-cancerous diseases and (iii) as a preventative measure for patients at risk of developing cancer based on genetic screening. For more information, visit: www.propanc.com. Forward-Looking Statements: All statements other than statements of historical fact contained herein are "forward-looking statements" for purposes of federal and state securities laws. Forward-looking statements may include the words "may," "will," "estimate," "intend," "continue," "believe," "expect," "plan" or "anticipate" and other similar words. Although we believe that the expectations reflected in our forward-looking statements are reasonable, actual results could differ materially from those projected or assumed. Our future financial condition and results of operations, as well as any forward-looking statements, are subject to change and to inherent risks and uncertainties including those regarding our earnings, revenues and financial condition, our ability to implement our plans, strategies and objectives for future operations, our ability to execute on proposed new products, services or development thereof, our ability to establish and maintain the proprietary nature of our technology through the patent process, our ability to license from others patents and patent applications, if necessary, to develop certain products, our ability to implement our long range business plan for various applications of our technology, our ability to enter into agreements with any necessary manufacturing, marketing and/or distribution partners for purposes of commercialization, the results of our clinical research and development, competition in the industry in which we operate, overall market conditions, and any statements or assumptions underlying any of the foregoing. Other risks, uncertainties and factors that could cause actual results to differ materially from those projected may be described from time to time in reports we file with the Securities and Exchange Commission, including our reports on Forms 10-K, 10-Q and 8-K. We do not intend, and undertake no obligation, to update any forward-looking statement contained herein, except as required by law.


News Article | May 23, 2017
Site: www.prweb.com

Vortex Biosciences, provider of circulating tumor cell (CTC) capture systems, today announced the publication of “Label-free isolation of prostate circulating tumor cells using Vortex microfluidic technology” in Nature Precision Oncology on May 8th. The peer reviewed publication is the result of a collaboration with Dr. Dino Di Carlo and Dr. Matthew Rettig at the University of California, Los Angeles. The publication describes the use of Vortex technology for the isolation and characterization of CTCs from 22 patients with advanced prostate cancer. CTCs can provide both genetic and phenotypic information about tumor evolution, potentially from both primary and metastatic sites. In this paper, the utility of the Vortex technology to support the capture and characterization of CTCs from prostate cancer patients was demonstrated. The Vortex technology isolates and collects CTCs directly from whole blood based on the greater deformability and larger size of the cells. CTCs are collected unbiased by their molecular characteristics and available for a wide range of analysis, providing a window into a patient’s cancer biology. The paper describes the capturing of CTCs from prostate cancer patients with high purity (from 1.74 to 37.59%) and efficiency (from 1.88 to 93.75 CTCs/7.5mL). Interestingly, atypical large circulating cells were identified in 5 age-matched healthy donors (46-77 years old; 1.25-2.5 CTCs/7.5 mL) but not in 5 healthy donors <30 years-old (21-27 years old; 0.00 CTC/7.5 mL). Using a threshold calculated from the 5 age-matched healthy donors (3.37 CTCs/mL), CTCs were identified at levels above the healthy threshold in 80% of the prostate cancer patients. A fraction of the cells collected (11.5%) did not express epithelial prostate markers (CK and/or PSA) and some instead expressed markers of epithelial-mesenchymal transition (EMT), i.e. vimentin and N-cadherin. "We are excited to see how effective the Vortex technology is for isolating CTCs independent of their epithelial properties, making them available for both genomic and phenotypic analysis,“ said Dr. Dino Di Carlo, Director of the Microfluidic Biotechnology Laboratory at UCLA and Director of the Cancer Nanotechnology Program of the Jonsson Comprehensive Cancer Center. "The work demonstrated in this paper shows what a powerful window into patient cancer biology CTCs can be with the right collection system." The fully automated VTX-1 Liquid Biopsy System from Vortex represents the next step in CTC isolation. The Vortex system utilizes a proprietary microfluidic chip to stably trap and capture CTCs in micro-scale vortices based on their larger size and greater deformability than the white and red blood cells. With excellent CTC recovery, best in class CTC purity, and collected CTCs being viable, and ready for downstream analysis, the VTX-1 offers the best CTC samples available today. About Vortex Biosciences Vortex Biosciences is a cancer research and diagnostics company that integrates cancer biology, microfluidic engineering and informatics to develop tools for isolating and characterizing circulating tumor cells. The Vortex VTX-1 instrument harvests intact circulating tumor cells from whole blood samples for use in downstream research and clinical applications such as patient stratification in clinical trials, monitoring disease progression and drug treatment effectiveness. With a mission to enable noninvasive diagnosis of cancer and real-time monitoring throughout a patient’s treatment, Vortex is at the forefront of accelerating cancer research and improving patient outcomes. Vortex is a core subsidiary of NetScientific plc, a transatlantic healthcare technology group with an investment strategy focused on sourcing, funding and commercializing technologies that significantly improve the health and well-being of people with chronic diseases. For more information, visit http://www.vortexbiosciences.com.


News Article | May 22, 2017
Site: marketersmedia.com

Customers looking for the latest Massage Therapist Service will soon be able to get involved with Dan Hendrix, Massage Therapist, LMT #404, EMT. Today Dane Hendrix, owner at Dan Hendrix, Massage Therapist, LMT #404, EMT releases details of the new Massage Therapist Service’s development for ballroom dancing Montgomery Al. The Massage Therapist Service for ballroom dancing is designed to appeal specifically to ballroom dancers and includes: Massage Therapy for Ballroom Dancing – This feature was included because it makes any fitness activity more rewarding. This is great news for the consumer as it avoids injury. Stretching and Good Nutrition – This was made part of the service, since it is a great combination for any dancer. Customers who invest in the service should enjoy this feature because it assists to provide maximum performance. Deep-Tissue Massage – Dan Hendrix, Massage Therapist, LMT #404, EMT made sure to make this part of the Massage Therapist Service’s development as it helps to reshape tightness of the body. Customers of the Massage Therapist Service, particularly ballroom dancers, will likely appreciate this because of movement limits and painful stretching. Dan Hendrix, when asked about the Massage Therapist Service said: Dance is a part of human culture as much as music and food. That includes literally thousands of dances and hundreds of dance styles. These are all taught under the umbrella of ballroom dance lessons. Some take a class to be able to learn how to dance at a wedding dance. That leads to a discovery of the joy, the exercise and challenge. Classes or private lessons are offered in dance schools, community centers, and YouTube instructional videos. Massage therapy along with stretching and good nutrition can make any fitness activity more rewarding. Patricia Burbank is a licensed Physical Therapist living in Montgomery Alabama. Ms. Burbank is also passionate about ballroom dance particularly Argentine Tango. Ms. Burbank offered her unique insight in these comments. “Serious dancers work hard to achieve a graceful and effortless look on the dance floor, which can result in painful muscle joint issues. Targeted bodywork and nutritional counseling can be a highly effective remedy. Dan Hendrix massage therapist and personal trainer for over 40 years is introducing this combination to all dancers, particularly ballroom dancers participants. This is the latest offering from Dan Hendrix, Massage Therapist, LMT #404, EMT and Dan Hendrix is particularly excited about this launch because of these highly effective remedies for ballroom dancers. Those interested in learning more about Dan Hendrix, Massage Therapist, LMT #404, EMT and their Massage Therapist Services for Ballroom Dancing Montgomery Al can do so on the website at https://www.advancedclinicmassage.com For more information, please visit https://www.advancedclinicmassage.com


Welcomes Appointment of Dr Scott Gottlieb as New FDA Commissioner MELBOURNE, AUSTRALIA--(Marketwired - May 16, 2017) - Propanc Biopharma Inc. ( : PPCHD) ("Propanc Biopharma" or "the Company"), a clinical stage biopharmaceutical company focusing on development of new and proprietary treatments for cancer patients suffering from solid tumors such as pancreatic, ovarian and colorectal cancers, today announced the Company awaits a response from the FDA to an Orphan Drug Designation (ODD) request for the use of its lead product, PRP, a solution for once daily intravenous administration of a combination of two pancreatic proenzymes trypsinogen and chymotrypsinogen. Submitted in February 2017, the proposed orphan drug indication for PRP is the treatment of pancreatic cancer, one of the most lethal malignancies with a median survival of 6 months and a 5-year survival rate of less than 5%. The lethal nature of this disease stems from its propensity to rapidly disseminate to the lymphatic system and distant organs, and is a major unmet medical issue. "We remain committed to providing a first-in-class treatment which can halt the growth and spread of aggressively spreading cancers like pancreatic cancer, but safer compared to standard treatment approaches," said Dr Julian Kenyon, Propanc's Chief Scientific Officer. "We will work with the FDA to provide a strong rationale why PRP qualifies for orphan drug designation, which provides exciting potential benefits to fast track the development process and provide attractive benefits for up to seven years when we achieve market approval." Responsible for 331,000 deaths worldwide in 2012, the aggressive biology and resistance to conventional therapeutic agents leads to a typical clinical presentation of incurable disease at the time of diagnosis. Propanc Biopharma intends to introduce a new therapy which targets and eradicates cancer stem cells, the cells responsible for the aggressive dissemination, resulting in a meaningful life extension for patients. "Propanc Biopharma is an innovative, entrepreneurial organization dedicated to the development of targeted and safer cancer therapeutics and we look forward to receiving a response from the FDA in the next two months regarding our orphan drug designation request, as we head towards First-In-Human studies for our lead product, PRP," said James Nathanielsz, Propanc's Chief Executive Officer. "We are also pleased to acknowledge the recent appointment of Dr Scott Gottlieb as the new commissioner at the FDA, who supports and welcomes innovation from industry, whilst continuing to protect the interests of public health. We believe there is an opportunity to set a new agenda for healthcare reform at the FDA, which could help drive change worldwide for future generations." Under the Orphan Drug Act (ODA), drugs, vaccines, and diagnostic agents qualify for orphan status if they are intended to treat a disease affecting less than 200,000 American citizens. Under the ODA, orphan drug sponsors qualify for seven-year FDA-administered market Orphan Drug Exclusivity (ODE), tax credits of up to 50% of R&D costs, R&D grants, waived FDA fees, protocol assistance and may get clinical trial tax incentives. The rationale for developing PRP, a formulation combining pancreatic proenzymes trypsinogen and chymotrypsinogen for intravenous administration for the proposed indication pancreatic cancer, is based on a set of in-vitro studies on cancer stem cells generated from pancreatic cancer cell lines as well as xenograft and syngeneic mouse models of pancreatic cancer. In summary, these data indicate that the dramatic reduction of cellular markers associated with the process of epithelial-mesenchymal transition (EMT) as a consequence of PRP treatment, could not only reverse the EMT process with the implication to stop tumor progression and metastasis, but also seem to suppress the development of cancer stem cells (CSCs). Consequently, these results are strong indicators of the therapeutic potential of PRP that could be categorized as an anti-CSC therapeutic drug. Recent development progress for PRP includes successful completion of a GLP-compliant, 28-day repeat-dose toxicity study with no toxicological findings after administration, indicating a broad safety margin and providing sufficient data to support a safe starting dose in First-In-Human studies. The Company has also commenced development of the GMP-compliant investigational medicinal product (IMP) manufacture of PRP to support preparation of a planned clinical trial application in the UK. Currently progressing towards First-In-Human studies, PRP aims to prevent tumor recurrence and metastasis from solid tumors. Eighty percent of all cancers are solid tumors and metastasis is the main cause of patient death from cancer. According to the World Health Organization, 8.2 million people died from cancer in 2012. Consequently, a report by IMS Health states innovative therapies are driving the global oncology market to meet demand, which is expected to reach $150 Billion by 2020. The Company's initial target patient populations are pancreatic, ovarian and colorectal cancers, representing a combined market segment of $14 Billion predicted in 2020, by GBI Research. To view Propanc Biopharma's "Mechanism of Action" video on anti-cancer product candidate, PRP, please click on the following link: http://www.propanc.com/news-media/video To be added to Propanc Biopharma's email distribution list, please click on the following link: http://ir.propanc.com/email-alerts and submit the online request form. Propanc Biopharma is a clinical stage biopharmaceutical company developing new cancer treatments initially for patients suffering from pancreatic, ovarian and colorectal cancers. We have developed a formulation of anti-cancer compounds, which exert a number of effects designed to control or prevent tumors from recurring and spreading throughout the body. Our products involve or employ pancreatic proenzymes, which are inactive precursors of enzymes. In the near term, we intend to target patients with limited remaining therapeutic options for the treatment of solid tumors. In future, we intend to develop our lead product to treat (i) early stage cancer and (ii) pre-cancerous diseases and (iii) as a preventative measure for patients at risk of developing cancer based on genetic screening. For more information, visit: www.propanc.com. All statements other than statements of historical fact contained herein are "forward-looking statements" for purposes of federal and state securities laws. Forward-looking statements may include the words "may," "will," "estimate," "intend," "continue," "believe," "expect," "plan" or "anticipate" and other similar words. Although we believe that the expectations reflected in our forward-looking statements are reasonable, actual results could differ materially from those projected or assumed. Our future financial condition and results of operations, as well as any forward-looking statements, are subject to change and to inherent risks and uncertainties including those regarding our earnings, revenues and financial condition, our ability to implement our plans, strategies and objectives for future operations, our ability to execute on proposed new products, services or development thereof, our ability to establish and maintain the proprietary nature of our technology through the patent process, our ability to license from others patents and patent applications, if necessary, to develop certain products, our ability to implement our long range business plan for various applications of our technology, our ability to enter into agreements with any necessary manufacturing, marketing and/or distribution partners for purposes of commercialization, the results of our clinical research and development, competition in the industry in which we operate, overall market conditions, and any statements or assumptions underlying any of the foregoing. Other risks, uncertainties and factors that could cause actual results to differ materially from those projected may be described from time to time in reports we file with the Securities and Exchange Commission, including our reports on Forms 10-K, 10-Q and 8-K. We do not intend, and undertake no obligation, to update any forward-looking statement contained herein, except as required by law.


News Article | May 19, 2017
Site: www.prnewswire.com

Similar to Dickey's franchise discount for military, this opportunity applies to law enforcement, firefighters and EMT. Dickey's recent involvement with first responders also includes the launch of Barbecue, Boots and Badges' 'Invest in a Vest' initiative, which aims to reduce risk for police officers by providing life-saving bullet proof vests and included a kickoff donation of ballistic plates to Dallas Police Department's entire gang unit.  In addition, Dickey's has a longstanding offer of 50% off for first responders that dine in at select locations. For more information on franchising opportunities with Dickey's Barbecue, please call 866-340-6188. To find the store nearest you, click here. Find Dickey's on Twitter, Facebook and Instagram. About Dickey's Barbecue Restaurants, Inc. Dickey's Barbecue Restaurants, Inc., the nation's largest barbecue chain was founded in 1941 by Travis Dickey. Today, all meats are still slow smoked on-site in each restaurant. The Dallas-based family-run barbecue franchise offers several slow-smoked meats and home style sides with 'No B.S. (Bad Stuff)' included. The fast-casual concept has expanded to nearly 600 locations in 44 states. In 2016, Dickey's won first place on Fast Casual's "Top 100 Movers and Shakers" list. Dickey's Barbecue Pit has also been recognized by Entrepreneur Magazine, Franchise Times, and Nation's Restaurant News. For more information on Dickey's awards, visit www.dickeys.com. About Barbecue, Boots & Badges Enthusiastically led by Maurine Dickey, Barbecue, Boots & Badges supports local law enforcement, firefighters and their families. The foundation is national, yet the support is intensely local — benefiting first responders who put their lives on the line every day, serving the public. The foundation exists to serve those who protect us. For more information, visit www.bbabfoundation.org. To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/dickeys-barbecue-pit-offers-special-franchise-deal-to-first-responders-300460524.html

Loading EMT Co. collaborators
Loading EMT Co. collaborators